Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isolagen completes efficacy portion of Phase III wrinkle therapy study
The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The company anticipates that top-line efficacy and safety
The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The company anticipates that top-line efficacy and safety
Under this co-promotion agreement, Paladin will maintain regulatory and supply responsibilities for Seasonale and will continue to support Seasonale using its national specialty sales force. P&G Pharmaceuticals Canada
The receipt of the State Food and Drug Administration (SFDA) certificates will allow Chindex to begin the sales process and launch official marketing programs for these products, creating
The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients. Approximately 14
According to the company, the integrated electrophysiology (EP) solution offers a software interface between the Hansen Medical Sensei robotic catheter system and the EnSite system advanced mapping software
Boston Scientific’s Promus stent is a private-labeled Xience V everolimus-eluting coronary stent system manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the
The acquisition of the products from these two different companies will provide Glenmark its first access to the growing Polish market, the largest pharmaceutical market in Central and
The company intends to use the net proceeds for working capital and general corporate purposes. The first closing occurred on June 30, 2008, and subsequent closings are subject
Biolitec, CoolTouch and Dornier market endovenous laser ablation products for use in procedures which Vnus believes infringe several of its patents. Vnus is seeking an injunction prohibiting these
The company will use the investment to fund the progression of its acute kidney disease therapy through Phase II clinical trials over the next three years. Funds will